Biochemical markers of atherosclerosis

Journal of Medical Biochemistry

Volumn 27, Issue 2, 2008, Pages 148-153

  Derić, Mirjana ^a   Kojić Damjanov, Sunčica ^a   Čabarkapa, Velibor ^a   Eremić, Nevena ^a  

^a Clinical Centre of Vojvodina   (Serbia)

Author keywords

Atherosclerosis; Biochemical markers; Lipids; Lipoproteins

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYTOKINE; FIBRINOGEN; IMMUNOGLOBULIN;

ATHEROSCLEROSIS; CIRCULATION; DIAGNOSTIC VALUE; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; REVIEW;

EID: 44649171852     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-008-0008-1     Document Type: Review

References (35)

1. Vukomirović, ed. Statistical Yearbook of Serbia 2005. Belgrade, Serbia, SCG: Statistical Office of the Republic of Serbia; 2005. p. 90.
2. The Expert Panel. The Third Report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002; 106: 3143-421.
3. De Backer G, Ambrosioni E, Borch-Johnsen K. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.
4. Das B, Daga MK, Gupta SK. Lipid Pentad Index: A novel bioindex for evaluation of lipid risk factors for atherosclerosis in young adolescents and children of premature coronary artery disease patients in India. Clin Bioch 2007; 40 (1-2): 18-24.
5. Bogavac-Stanojević N, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Spasić S, Kalimanovska- Oštrić D. Lipid and inflammatory markers for the prediction of coronary artery disease: A multi-marker approach. Clin Biochem 2007; 40 (13-14): 1000-6.
6. Kondo K, Kitagawa K, Nagai Y, Yamagami H, Hashimoto H, Hougaku H, et al. Associations of soluble adhesion molecule-1 with carotid atherosclerosis progression. Atherosclerosis 2005; 179 (1): 155-60.
7. Lind L. Circulating markers of inflamation and atherosclerosis. Atherosclerosis 2003; 169 (2): 203-14.
8. Koenig W. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Internat J Cardiol 2005; 98 (2): 199-206.
9. Wilson AM, Ryan MC, Boyle AJ. The novel role of Creactive protein in cardiovascular disease: Risk marker or pathogen. Internat J Cardiol 2006; 106 (3): 291-7.
10. Paffen E, De Maat MPM. C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res 2006; 71 (1): 30-9.
11. Pandolfi A. C-reactive protein: A potential new molecular link between inflammation, thrombosis and vascular cell proliferation? Cardiovac Res 2005; 68 (1): 3-4.
12. Sacks FM. Apolipoprotein story. Atherosclerosis Suppl 2006; 7 (4): 23-7.
13. Chan DC, Watts GF. Apolipoproteins as markers and managers of coronary risk. QJM 2006; 99 (5): 277-87.
14. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: The comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 2006; 367 (1-2): 36-47.
15. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99 (1): 1-14.
16. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurement of apolipoproteins A-I and B. III. Compatibility of apolipoprotein A-I values by use of international reference material. Clin Chem 1993; 39: 773-81.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 449-502.
18. Walldius G, Junger I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
19. Miller M, Ginsberg HN, Schaefer EJ. Relative Atherogenicity and Predictive Value of Non-High-Density Lipoprotein Cholesterol for Coronary Heart Disease. Am J Cardiol 2008; 101 (7): 1003-8.
20. Ballantyne C, Arroll B, Shepherd J. Lipids and CVD management: towards a global consensus. Eur Heart J 2005; 26 (21): 2224-31.
21. Dobiášova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoblipoprotein-depleted plasma (FERHDL). Clin Biochem 2001; 34 (7): 583-8.
22. Rajappa M, Sridhar MG, Balachander J, Sethuraman KR. Lipoprotein (a) and comprehensive lipid tetrad index as a marker for coronary artery disease in NIDDM patients in South India. Clin Chim Acta 2006; 372 (1-2): 70-5.
23. Kushner I, Rzewnicki D, Samols D. What Does Minor Elevation of C-Reactive Protein Signify? Am J Med 2006; 119 (2): 166.e17-e28.
24. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. N Engl J Med 2002; 347 (20): 1557-65.
25. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
26. Ignjatović S, Majkić N. Biomarkers of diseases: An evidence-based approach. Jugoslov Med Biohem 2006; 25: 227-33.
27. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061-5.
28. Kamath S, Lip GYH. Fibrinogen: biochemistry, epidemiology and determinants. Q J Med 2003; 96: 711-29.
29. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE. Jr, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50 (7): e1-e157.
30. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochmanet JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.
31. Francisco G, Hernández C, Simó R. Serum markers of vascular inflammation in dyslipemia. Clin Chim Acta 2006; 369 (1): 1-16.
32. Aristoteli LP, Moller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006; 184 (2): 342-7.
33. Panteghini M. Biochemical markers of cardiac diseases. Jugoslov Med Biohem 2004; 23: 210-11.
34. Lazzerini PE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Galeazzi M, et al. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmunity Rev 2007; 6 (7): 503-9.
35. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.